Fig. 3
From: IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience
Chemotherapy lines and their duration. Number of chemotherapy (CT) lines in 15 patients treated with chemotherapy at recurrence/progression of disease, and duration in month for each CT line, by mutational status. Only the patient with IDH1/2 mut who received chemotherapy according to Euro-B.O.S.S. protocol [11] for a dedifferentiated recurrence, had tumor shrinkage. One patient received adjuvant chemotherapy after dedifferentiated recurrence. The other 13 patients had disease progression after 2-6 months in all chemotherapy lines: 5 of them received rapamycin and cyclophosphamide (but only one achieved a disease stabilization as best response) and 2 with hedgehog inhibitors